Glimepirid Stada

Glimepirid Stada is a prescription medication that contains the active ingredient glimepiride, a sulfonylurea oral antidiabetic agent. It is marketed in the European Union and is supplied as an oral tablet for the management of blood glucose levels in adults with type 2 diabetes mellitus.

Glimepirid Stada is indicated for the treatment of type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient. It may be used alone or in combination with other antidiabetic agents. - Improves glycemic control in adults with type 2 diabetes. - Can be combined with metformin when monotherapy is inadequate. - May be added to basal insulin regimens to reduce fasting glucose. - Used as part of a comprehensive diabetes management plan including lifestyle modification. - Suitable for patients who require an oral sulfonylurea to stimulate insulin secretion.

Glimepirid Stada may cause a range of side effects, some of which are more frequently observed than others. Common: - Mild hypoglycemia, especially when meals are missed. - Nausea or abdominal discomfort. - Headache or dizziness. - Weight gain due to increased insulin activity. Serious: - Severe hypoglycemia requiring assistance. - Allergic reactions such as rash, itching, or swelling. - Hepatic dysfunction indicated by elevated liver enzymes. - Hematologic abnormalities like leukopenia or thrombocytopenia.

Before starting Glimepirid Stada, certain precautions should be considered to ensure safe use. - Assess renal and hepatic function, as impairment may affect drug clearance. - Monitor blood glucose regularly to detect hypoglycemia early. - Use caution in elderly patients who may be more susceptible to low blood sugar. - Discuss pregnancy or breastfeeding plans with a healthcare professional; safety data are limited. - Review any history of cardiovascular disease, as sulfonylureas may influence cardiac outcomes. - Avoid abrupt discontinuation without medical guidance to prevent rebound hyperglycemia.

Glimepirid Stada can interact with several medications, altering its effectiveness or safety profile. Avoid: - Concurrent use with other sulfonylureas or insulin that may increase hypoglycemia risk. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise glimepiride levels. - MAO inhibitors, which may potentiate hypoglycemic effects. Use with caution: - Beta‑blockers, as they may mask hypoglycemia symptoms. - Thiazide diuretics, which can affect glucose tolerance. - Corticosteroids, which may increase blood glucose and require dose adjustments. - Antifungal agents like ketoconazole, which may modestly increase drug exposure.